Truist Financial reissued their buy rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a research report report published on Monday, Benzinga reports. Truist Financial currently has a $74.00 target price on the stock.
Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group boosted their price target on shares of Tourmaline Bio from $41.00 to $72.00 and gave the stock a buy rating in a research note on Wednesday, March 20th. HC Wainwright restated a buy rating and issued a $48.00 price target on shares of Tourmaline Bio in a research note on Wednesday, March 20th. Finally, Leerink Partnrs restated an outperform rating on shares of Tourmaline Bio in a research note on Thursday, December 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tourmaline Bio presently has an average rating of Buy and a consensus target price of $61.80.
View Our Latest Stock Report on TRML
Tourmaline Bio Stock Performance
Insider Transactions at Tourmaline Bio
In other news, Director Mark Mcdade acquired 100,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was acquired at an average cost of $32.50 per share, with a total value of $3,250,000.00. Following the transaction, the director now owns 448,431 shares in the company, valued at $14,574,007.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 16.50% of the company’s stock.
Institutional Investors Weigh In On Tourmaline Bio
A number of institutional investors and hedge funds have recently bought and sold shares of TRML. BML Capital Management LLC purchased a new stake in Tourmaline Bio in the fourth quarter valued at $6,427,000. Vivo Capital LLC purchased a new stake in Tourmaline Bio in the fourth quarter valued at $15,495,000. Jump Financial LLC purchased a new stake in Tourmaline Bio in the fourth quarter valued at $380,000. Dimensional Fund Advisors LP purchased a new stake in Tourmaline Bio in the fourth quarter valued at $546,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Tourmaline Bio in the fourth quarter valued at $236,000. 91.89% of the stock is owned by hedge funds and other institutional investors.
Tourmaline Bio Company Profile
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Recommended Stories
- Five stocks we like better than Tourmaline Bio
- Upcoming IPO Stock Lockup Period, Explained
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Does Downgrade Mean in Investing?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 5 discounted opportunities for dividend growth investors
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.